Table 1 Epidemiological, clinical, laboratory and evolution data, according to microbiological (Mansonella perstans vs co-infections) and clinical associations (symptomatic vs asymptomatic)
All patients | Microbiological association | Clinical association | |||||
|---|---|---|---|---|---|---|---|
N = 503 (100%) | Only M. perstans n1 = 308 (61.2%) | Co-infections n2 = 195 (38.8%) | P-value* | Symptomatic n3 = 228 (45.3%) | Asymptomatic n4 = 275 (54.7%) | P-value* | |
Epidemiological data | |||||||
Male | 239 (47.5) | 149 (48.4) | 90 (46.2) | 0.627 | 94 (41.2) | 145 (52.7) | 0.010* |
Female | 264 (52.5) | 159 (51.6) | 105 (53.8) | 134 (58.8) | 130 (47.3) | ||
Age, mean ± SD, years | 44.6 ± 18.2 | 45.4 ± 17.8 | 43.3 ± 18.7 | 0.228 | 44.8 ± 18.6 | 44.4 ± 17.8 | 0.771 |
0–24 | 93 (18.5) | 50 (16.2) | 43 (22.1) | 44 (19.3) | 49 (17.8) | ||
25–50 | 205 (40.8) | 129 (41.9) | 76 (39.0) | 93 (40.8) | 112 (40.7) | ||
> 50 | 205 (40.8) | 129 (41.9) | 76 (39.0) | 91 (39.9) | 114 (41.5) | ||
Months in Spain, mean ± SD | 8.6 ± 18.0 | 8.2 ± 19.9 | 9.2 ± 14.4 | 0.540 | 8.4 ± 15.7 | 8.7 ± 19.7 | 0.850 |
Clinical data | |||||||
Asymptomatic | 275 (54.7) | 194 (63.0) | 81 (41.5) | < 0.001* | |||
Symptomatic | 228 (45.3) | 114 (37.0) | 114 (58.5) | ||||
Pruritus | 190 (37.8) | 88 (28.6) | 102 (52.3) | ||||
Arthralgia | 50 (9.9) | 33 (10.7) | 17 (8.7) | ||||
Abdominal pain | 15 (3.0) | 12 (3.9) | 3 (1.5) | ||||
Subcutaneous step (calabar swelling) | 18 (3.6) | 3 (1.0) | 15 (7.7) | ||||
Laboratory data | |||||||
Eosinophilia, × 106 eosinophils/L | N = 503 | n1 = 308 | n2 = 195 | n3 = 228 | n4 = 275 | ||
Without eosinophilia (< 450) | 105 (20.9) | 69 (22.4) | 36 (18.5) | < 0.001* | 54 (23.7) | 51 (18.5) | < 0.001* |
Relative eosinophilia (< 450 + > 5%) | 58 (11.5) | 54 (17.5) | 4 (2.1) | 22 (9.6) | 36 (13.1) | ||
Mild eosinophilia (450–999) | 159 (31.6) | 104 (33.8) | 55 (28.2) | 53 (23.2) | 106 (38.5) | ||
Moderate eosinophilia (1000–2999) | 154 (30.6) | 75 (24.4) | 79 (40.5) | 78 (34.2) | 76 (27.6) | ||
Severe eosinophilia (≥ 3000) | 27 (5.4) | 6 (1.9) | 21 (10.8) | 21 (9.2) | 6 (2.2) | ||
Mean ± SD | 1151.7 ± 1296.5 | 819.8 ± 863.0 | 1465.4 ± 1707.2 | 1252.0 ± 1387.7 | 919.2 ± 1197.4 | ||
Immunoglobulin E, U/ml | N = 491 | n1 = 300 | n2 = 191 | n3 = 222 | n4 = 269 | ||
Normal (< 200) | 49 (10.0) | 37 (12.3) | 12 (6.3) | 0.001* | 20 (9.0) | 29 (10.8) | 0.749 |
Mild hyper-IgE (200–399) | 57 (11.6) | 46 (15.3) | 11 (5.8) | 23 (10.4) | 34 (12.6) | ||
Moderate hyper-IgE (400–999) | 105 (21.4) | 61 (20.3) | 44 (23.0) | 48 (21.6) | 57 (21.2) | ||
Severe hyper-IgE (≥ 1000) | 280 (55.7) | 156 (52.0) | 124 (64.9) | 131 (59.0) | 149 (55.4) | ||
Mean ± SD | 1417.3 ± 1132.9 | 1310.0 ± 1111.7 | 1585.8 ± 1148.2 | 1442.2 ± 1153.7 | 1396.8 ± 1117.2 | ||
Evolution | |||||||
Healing** | 240 (47.7) | 147 (47.7) | 93 (47.7) | 0.599 | 118 (51.8) | 122 (44.4) | 0.247 |
No | 18 (3.6) | 9 (2.9) | 9 (4.6) | 7 (3.1) | 11 (4.0) | ||
No follow-up | 245 (48.7) | 152 (49.4) | 93 (47.7) | 103 (45.2) | 142 (51.6) | ||